The treatment of relapsed or refractory Acute Lymphocytic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) with chimeric antigen receptor (CAR) T-cells that target CD19 (CAR-CD19 T cells) has led to FDA and EMA approvals of the adoptive cell therapies tisagenlecleucel and axicabtagene ciloleucel [1, 2]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.